InflaRx Pulls Off $150 Million Capital Raise as Pipeline Pivot Gathers Pace

InflaRx raises $150M from TCGX and Farallon, cuts costs by 30%, and advances kidney drug Izicopan toward Phase 2 trials despite going-concern risk.

InflaRx has pulled off a hefty $150 million capital injection, placing 75 million shares at $2 apiece in a deal that brings heavyweight backers TCGX and Farallon Capital on board. The biotech specialist, which has been wrestling with a cash burn and a flagging share price, expects the transaction to close in May 2026.

The fundraising comes as the company sharpens its strategic focus. Management is now betting heavily on Izicopan (INF904), a drug candidate for kidney diseases, and is preparing a Phase 2 trial for ANCA-associated vasculitis. Further studies across other renal indications are in the pipeline, with initial clinical data expected in 2027.

The shift in emphasis has meant scaling back elsewhere. InflaRx will only pursue its Hidradenitis Suppurativa programme with a partner going forward. The company has also slashed its workforce by 30%, driving operating expenses down to €7.5 million in the first quarter of 2026, compared with a higher figure a year earlier.

That cost discipline is already showing up on the bottom line. The net loss narrowed to €5.6 million in the first three months of 2026, down from €8.3 million in the same period last year. InflaRx no longer generates any revenue from its former product GOHIBIC.

Despite the fresh capital, the company continues to flag a going-concern risk. Current funds are expected to last into 2027, and management plans to lay out further strategic detail at a Capital Markets Day in the summer.

Safety Data Adds to the Case for Izicopan

The stock has been under pressure, closing at $1.97 on 5 May — a drop of over 7% on the previous session — giving the company a market capitalisation of roughly $142 million. That weakness stands in contrast to the progress being made on the science.

InflaRx recently released results from a GSH-trapping assay for Izicopan, which pointed to a favourable metabolic profile with only minimal reactive metabolites detected. Compared with standard benchmarks for similar inhibitors, the data is seen as an encouraging sign for the drug’s potential tolerability.

The company has also resolved a regulatory headache: it now meets the Nasdaq minimum bid price requirement again, removing the immediate threat of delisting.

Analyst Conviction Holds Firm

Even with the share price languishing well below the $2 placement price, analysts remain bullish. The average price target stands at $8.62, and several firms have reaffirmed buy recommendations in recent weeks.

The next major catalyst comes on 7 May, when InflaRx reports first-quarter 2026 earnings before the US market open. A conference call will follow, with investors hoping for more colour on the clinical pipeline and the timeline for Izicopan’s development.